thalidomide has been researched along with oligonucleotides in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Al Ali, NH; Basiorka, A; Boultwood, J; Caceres, G; Daugherty, FJ; Fulp, WJ; Johnson, J; Komrokji, RS; Lee, JH; List, AF; Littleton, N; Liu, K; McGraw, K; Pellagatti, A; Smith, LJ; Sokol, L; Wei, S; Wells, RA; Yip, BH; Zhang, L; Zhang, LM | 1 |
| Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T | 1 |
| Marafini, I; Monteleone, G; Salvatori, S; Troncone, E | 1 |
3 review(s) available for thalidomide and oligonucleotides
| Article | Year |
|---|---|
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Novel therapies in low- and high-risk myelodysplastic syndrome.
Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous | 2019 |
TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Oligonucleotides; Phosphodiesterase 4 Inhibitors; Thalidomide; Thiazoles; Transforming Growth Factor beta | 2020 |
1 other study(ies) available for thalidomide and oligonucleotides
| Article | Year |
|---|---|
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Topics: Base Sequence; Dexamethasone; Drug Resistance; Erythroid Precursor Cells; Erythropoiesis; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lenalidomide; Molecular Sequence Data; Myelodysplastic Syndromes; Oligonucleotides; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Statistics, Nonparametric; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |